MX2024008413A - Compuestos macrocíclicos y uso como inhibidores de cinasas. - Google Patents
Compuestos macrocíclicos y uso como inhibidores de cinasas.Info
- Publication number
- MX2024008413A MX2024008413A MX2024008413A MX2024008413A MX2024008413A MX 2024008413 A MX2024008413 A MX 2024008413A MX 2024008413 A MX2024008413 A MX 2024008413A MX 2024008413 A MX2024008413 A MX 2024008413A MX 2024008413 A MX2024008413 A MX 2024008413A
- Authority
- MX
- Mexico
- Prior art keywords
- macrocyclic compounds
- kinase inhibitors
- compounds
- macrocyclic
- present disclosure
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 4
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296705P | 2022-01-05 | 2022-01-05 | |
| US202263435654P | 2022-12-28 | 2022-12-28 | |
| PCT/US2023/060039 WO2023133375A1 (en) | 2022-01-05 | 2023-01-03 | Macrocyclic compounds and use as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008413A true MX2024008413A (es) | 2024-09-17 |
Family
ID=87074235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008413A MX2024008413A (es) | 2022-01-05 | 2023-01-03 | Compuestos macrocíclicos y uso como inhibidores de cinasas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250074920A1 (https=) |
| EP (1) | EP4460498A4 (https=) |
| JP (1) | JP2025503592A (https=) |
| KR (1) | KR20240131416A (https=) |
| AU (1) | AU2023204770A1 (https=) |
| CA (1) | CA3246487A1 (https=) |
| IL (1) | IL314070A (https=) |
| MX (1) | MX2024008413A (https=) |
| TW (1) | TW202334168A (https=) |
| WO (1) | WO2023133375A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024266587A1 (en) * | 2023-05-02 | 2025-09-11 | Blossomhill Therapeutics, Inc. | Egfr inhibitors for treating disease |
| WO2025212729A1 (en) * | 2024-04-03 | 2025-10-09 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and their use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03376B (me) * | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| US20160031888A1 (en) * | 2013-03-13 | 2016-02-04 | Boston Biomedical, Inc. | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
| ES2933350T3 (es) * | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| TWI707852B (zh) * | 2015-09-02 | 2020-10-21 | 美商林伯士拉克許米公司 | Tyk2 抑制劑及其用途 |
| EP4178958A4 (en) * | 2020-07-10 | 2024-12-11 | Blossomhill Therapeutics, Inc. | MACROCYCLES AND THEIR USE |
-
2023
- 2023-01-03 AU AU2023204770A patent/AU2023204770A1/en active Pending
- 2023-01-03 WO PCT/US2023/060039 patent/WO2023133375A1/en not_active Ceased
- 2023-01-03 MX MX2024008413A patent/MX2024008413A/es unknown
- 2023-01-03 KR KR1020247025807A patent/KR20240131416A/ko active Pending
- 2023-01-03 CA CA3246487A patent/CA3246487A1/en active Pending
- 2023-01-03 JP JP2024540747A patent/JP2025503592A/ja active Pending
- 2023-01-03 EP EP23737695.9A patent/EP4460498A4/en active Pending
- 2023-01-03 US US18/725,951 patent/US20250074920A1/en active Pending
- 2023-01-03 IL IL314070A patent/IL314070A/en unknown
- 2023-01-05 TW TW112100378A patent/TW202334168A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3246487A1 (en) | 2023-07-13 |
| US20250074920A1 (en) | 2025-03-06 |
| TW202334168A (zh) | 2023-09-01 |
| EP4460498A1 (en) | 2024-11-13 |
| EP4460498A4 (en) | 2026-03-25 |
| JP2025503592A (ja) | 2025-02-04 |
| AU2023204770A1 (en) | 2024-07-18 |
| KR20240131416A (ko) | 2024-08-30 |
| WO2023133375A1 (en) | 2023-07-13 |
| IL314070A (en) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| GT201400090A (es) | 2-tiopirimidinonas | |
| CO2020007044A2 (es) | Derivados de pirrol como inhibidores de acc | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| MX2024008413A (es) | Compuestos macrocíclicos y uso como inhibidores de cinasas. | |
| MX2021007426A (es) | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina. | |
| CL2023000061A1 (es) | Macrociclos y su uso | |
| CR20240533A (es) | Macrociclos de indazol y su uso | |
| MX2024014995A (es) | Macrociclos que contienen indazol y su uso | |
| MX2021014961A (es) | Compuestos triciclicos y su uso. | |
| CO2025016647A2 (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| MX2023000198A (es) | Inhibidores de atr y usos de estos. | |
| CO2022017969A2 (es) | Compuestos de imidazopiridazina con actividad como inhibidores de alk2 | |
| CO2024000832A2 (es) | Inhibidores de transglutaminasas | |
| MX2026000140A (es) | Compuestos macrociclicos y uso como inhibidores de tyk2 | |
| MX2021011979A (es) | Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa. | |
| DOP2025000274A (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| MX2023007297A (es) | 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1. | |
| UY39875A (es) | Pirazolopirimidinas y sus usos como inhibidores de pdgfr |